Hepatitis B screening with conventional and emerging biomarkers
DOI:
https://doi.org/10.59093/27112322.169Keywords:
immunologic monitoring, hepatitis B virus, liver failure , hepatitis B surface antigens.Abstract
Long-term treatment of chronic hepatitis due to hepatitis B virus (HBV) with nucleotide/nucleoside analogues (NUC) can stop the progression of the disease and the development of liver cirrhosis with its complications, including the appearance hepatocellular carcinoma (HCC); and on many specific occasions, prevent HBV reactivation, the development of severe acute hepatitis, and in some cases, acute liver failure. However, the use of NUC does not achieve a functional cure, that is, the disappearance of the surface antigen of the hepatitis B virus (HBsAg), and the most important thing is that there are still no known markers that allow us to define in which Antiviral treatment can be withdrawn at this time.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Hepatología’s authorship policy is based on the criteria established by the International Committee of Medical Journal Editors (ICMJE) to credit a person for their work while assigning them responsibility for its publication.
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
